ArriVent says furmonertinib missed its main goal in a late-stage lung cancer studyArriVent BioPharma·Biotech·6 Oct·BioPharma Dive
Iambic Therapeutics raises $150 million in IPODeal · IPOIambic Therapeutics·Biotech·14 Oct·BioPharma Dive
BioNTech says its mRNA head and neck cancer therapy missed a trial objectiveBioNTech·Biotech·13 Oct·BioPharma Dive